论文部分内容阅读
盈利动能大幅提升是鱼跃医疗新入选166的主要原因。最新综合目标价为30.98元,12个月涨升空间达到23.62%。医用临床系列占比不高,但潜力较大10月13日晚公司公告:鱼跃医疗200万收购镇江康利医疗器械有限公司20%股权,同时增资1000万元人民币。公司11年上半年实现收入6.09亿(同比增40.17%),其中医用供氧(2.05亿)、康复护理(3.27亿)、医用临床系列(0.76
The substantial increase of profitability is the main reason for the new selection of diving medical166. The latest comprehensive target price of 30.98 yuan, 12 months rose space up to 23.62%. The proportion of medical clinical series is not high but with great potential On the evening of October 13, the company announced that Di Yu Medical paid a 20% stake in Zhenjiang Kangli Medical Devices Co., Ltd. while increasing its capital by 10 million yuan. The Company achieved a revenue of 609 million in the first half of this year (up 40.17% over the same period), of which medical oxygen supply (205 million), rehabilitation nursing (327 million) and medical clinical series (0.76